231. Alpha-1-antitrypsin deficiency Clinical trials / Disease details
Clinical trials : 93 / Drugs : 77 - (DrugBank : 8) / Drug target genes : 10 - Drug target pathways : 36
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04764448 (ClinicalTrials.gov) | February 12, 2021 | 27/1/2021 | A Study of Belcesiran in Patients With AATLD | A Phase 2, Randomized, Double-blind, Placebo-Controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease | Alpha 1-Antitrypsin Deficiency | Drug: Belcesiran;Other: Placebo | Dicerna Pharmaceuticals, Inc. | NULL | Recruiting | 18 Years | 75 Years | All | 46 | Phase 2 | Australia;Austria;Belgium;Canada;France;Germany;Ireland;Netherlands;New Zealand;Portugal;Spain;Sweden;United Kingdom |
| 2 | NCT04174118 (ClinicalTrials.gov) | October 24, 2019 | 6/11/2019 | Study of DCR-A1AT in Healthy Adult Volunteers | A Phase 1 Single Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered Belcesiran in Healthy Adult Volunteers | Alpha 1-Antitrypsin Deficiency | Drug: belcesiran;Drug: Placebo | Dicerna Pharmaceuticals, Inc. | NULL | Active, not recruiting | 18 Years | 55 Years | All | 30 | Phase 1 | New Zealand;Sweden |